Overview

Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

Status:
Completed

Trial end date:
2016-09-18

Target enrollment:

Participant gender:

Summary

This study will compare the results of stem cell mobilization using drugs called filgrastim (Neupogen) and plerixafor with the results of stem cell mobilization using drugs called XM02 filgrastim (Granix) and plerixafor.

Phase:

Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Treatments:

JM 3100
Lenograstim
Plerixafor
Sargramostim